SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern

  1. David W Hawman  Is a corresponding author
  2. Kimberly Meade-White
  3. Jacob Archer
  4. Shanna S Leventhal
  5. Drew Wilson
  6. Carl Shaia
  7. Samantha Randall
  8. Amit P Khandhar
  9. Kyle Krieger
  10. Tien-Ying Hsiang
  11. Michael Gale Jr
  12. Peter Berglund
  13. Deborah Heydenburg Fuller
  14. Heinz Feldmann  Is a corresponding author
  15. Jesse Erasmus  Is a corresponding author
  1. National Institute of Allergy and Infectious Diseases, United States
  2. HDT Bio, United States
  3. University of Washington, United States
  4. The University of Washington, United States

Abstract

Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late-2021 with resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants of concern (VoC) and evidence that existing vaccines that were designed to protect from the original strains of SARS-CoV-2 may have reduced potency for protection from infection against these VoC is driving continued development of second generation vaccines that can protect against multiple VoC. In this report, we evaluated an alphavirus-based replicating RNA vaccine expressing Spike proteins from the original SARS-CoV-2 Alpha strain and recent VoCs delivered in vivo via a lipid inorganic nanoparticle. Vaccination of both mice and Syrian Golden hamsters showed that vaccination induced potent neutralizing titers against each homologous VoC but reduced neutralization against heterologous challenges. Vaccinated hamsters challenged with homologous SARS-CoV2 variants exhibited complete protection from infection. In addition, vaccinated hamsters challenged with heterologous SARS-CoV-2 variants exhibited significantly reduced shedding of infectious virus. Our data demonstrate that this vaccine platform can be updated to target emergent VoCs, elicits significant protective immunity against SARS-CoV2 variants and supports continued development of this platform.

Data availability

All data generated or analyzed during this study are included in the figures and supporting files

Article and author information

Author details

  1. David W Hawman

    Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, United States
    For correspondence
    david.hawman@nih.gov
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8233-8176
  2. Kimberly Meade-White

    Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, United States
    Competing interests
    No competing interests declared.
  3. Jacob Archer

    HDT Bio, Seattle, United States
    Competing interests
    Jacob Archer, is a consultant for InBios.
  4. Shanna S Leventhal

    Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, United States
    Competing interests
    No competing interests declared.
  5. Drew Wilson

    Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, United States
    Competing interests
    No competing interests declared.
  6. Carl Shaia

    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Hamilton, United States
    Competing interests
    No competing interests declared.
  7. Samantha Randall

    Department of Microbiology, University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  8. Amit P Khandhar

    HDT Bio, Seattle, United States
    Competing interests
    Amit P Khandhar, has equity interest in HDT Bio. Is a co-inventors on U.S. patent application no. 62/993,307 Compositions and methods for delivery of RNA" pertaining to the LION formulation.".
  9. Kyle Krieger

    HDT Bio, Seattle, United States
    Competing interests
    No competing interests declared.
  10. Tien-Ying Hsiang

    Department of Immunology, The University of Washington, Seattle, United States
    Competing interests
    No competing interests declared.
  11. Michael Gale Jr

    Department of Immunology, University of Washington, Seattle, United States
    Competing interests
    Michael Gale, has equity interest in HDT Bio..
  12. Peter Berglund

    HDT Bio, Seattle, United States
    Competing interests
    Peter Berglund, has equity interest in HDT Bio. Is a consultant for Arcturus, Sensei, and Next Phase..
  13. Deborah Heydenburg Fuller

    Department of Microbiology, University of Washington, Seattle, United States
    Competing interests
    Deborah Heydenburg Fuller, has equity interest in HDT Bio. Is a consultant for Gerson Lehrman Group, Orlance, Abacus Bioscience, Neoleukin Therapeutics..
  14. Heinz Feldmann

    Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, United States
    For correspondence
    feldmannh@niaid.nih.gov
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9448-8227
  15. Jesse Erasmus

    HDT Bio, Seattle, United States
    For correspondence
    jesse.erasmus@hdt.bio
    Competing interests
    Jesse Erasmus, has equity interest in HDT Bio. Is a consultant for InBios. Is a co-inventors on U.S. patent application no. 62/993,307 Compositions and methods for delivery of RNA" pertaining to the LION formulation.".
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1612-2697

Funding

National Institute of Allergy and Infectious Diseases

  • Michael Gale Jr
  • Jesse Erasmus

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

  • David W Hawman
  • Kimberly Meade-White
  • Shanna S Leventhal
  • Drew Wilson
  • Carl Shaia
  • Heinz Feldmann

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experiments were approved by the corresponding institutional animal care and use committee and performed by experienced personnel under veterinary oversight (Protocol #2020-63).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,408
    views
  • 298
    downloads
  • 30
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David W Hawman
  2. Kimberly Meade-White
  3. Jacob Archer
  4. Shanna S Leventhal
  5. Drew Wilson
  6. Carl Shaia
  7. Samantha Randall
  8. Amit P Khandhar
  9. Kyle Krieger
  10. Tien-Ying Hsiang
  11. Michael Gale Jr
  12. Peter Berglund
  13. Deborah Heydenburg Fuller
  14. Heinz Feldmann
  15. Jesse Erasmus
(2022)
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern
eLife 11:e75537.
https://doi.org/10.7554/eLife.75537

Share this article

https://doi.org/10.7554/eLife.75537

Further reading

    1. Immunology and Inflammation
    Ning Song, Hang Gao ... Wenlong Zhang
    Research Article

    Gout is a prevalent form of inflammatory arthritis that occurs due to high levels of uric acid in the blood leading to the formation of urate crystals in and around the joints, particularly affecting the elderly. Recent research has provided evidence of distinct differences in the gut microbiota of patients with gout and hyperuricemia compared to healthy individuals. However, the link between gut microbiota and age-related gout remained underexplored. Our study found that gut microbiota plays a crucial role in determining susceptibility to age-related gout. Specifically, we observed that age-related gut microbiota regulated the activation of the NLRP3 inflammasome pathway and modulated uric acid metabolism. More scrutiny highlighted the positive impact of ‘younger’ microbiota on the gut microbiota structure of old or aged mice, enhancing butanoate metabolism and butyric acid content. Experimentation with butyrate supplementation indicated that butyric acid exerts a dual effect, inhibiting inflammation in acute gout and reducing serum uric acid levels. These insights emphasize the potential of gut microbiome rejuvenation in mitigating senile gout, unraveling the intricate dynamics between microbiota, aging, and gout. It potentially serves as a therapeutic target for senile gout-related conditions.

    1. Immunology and Inflammation
    Weigao Zhang, Hu Liu ... Dan Weng
    Research Article

    As a central hub for metabolism, the liver exhibits strong adaptability to maintain homeostasis in response to food fluctuations throughout evolution. However, the mechanisms governing this resilience remain incompletely understood. In this study, we identified Receptor interacting protein kinase 1 (RIPK1) in hepatocytes as a critical regulator in preserving hepatic homeostasis during metabolic challenges, such as short-term fasting or high-fat dieting. Our results demonstrated that hepatocyte-specific deficiency of RIPK1 sensitized the liver to short-term fasting-induced liver injury and hepatocyte apoptosis in both male and female mice. Despite being a common physiological stressor that typically does not induce liver inflammation, short-term fasting triggered hepatic inflammation and compensatory proliferation in hepatocyte-specific RIPK1-deficient (Ripk1-hepKO) mice. Transcriptomic analysis revealed that short-term fasting oriented the hepatic microenvironment into an inflammatory state in Ripk1-hepKO mice, with up-regulated expression of inflammation and immune cell recruitment-associated genes. Single-cell RNA sequencing further confirmed the altered cellular composition in the liver of Ripk1-hepKO mice during fasting, highlighting the increased recruitment of macrophages to the liver. Mechanically, our results indicated that ER stress was involved in fasting-induced liver injury in Ripk1-hepKO mice. Overall, our findings revealed the role of RIPK1 in maintaining liver homeostasis during metabolic fluctuations and shed light on the intricate interplay between cell death, inflammation, and metabolism.